|
US5834428A
(en)
*
|
1995-04-14 |
1998-11-10 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
US6184201B1
(en)
*
|
1995-04-14 |
2001-02-06 |
Nps Allelix Corp. |
Intestinotrophic glucagon-like peptide-2 analogs
|
|
EP1231219B1
(en)
|
1996-04-12 |
2010-08-25 |
1149336 Ontario Inc. |
GLucagon-like peptide-2 analogs
|
|
US20020025933A1
(en)
*
|
1996-08-30 |
2002-02-28 |
Knudsen Liselotte Bjerre |
GLP-2 derivatives
|
|
CA2236519C
(en)
*
|
1997-05-02 |
2011-09-13 |
1149336 Ontario Inc. |
Methods of enhancing functioning of the large intestine
|
|
SE9802080D0
(sv)
*
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
|
CN1495198A
(zh)
|
1998-12-07 |
2004-05-12 |
�о���Ӧ�ÿ�ѧЭ��ɷ�����˾ |
胰高血糖素样肽-1的类似物
|
|
GB9930882D0
(en)
*
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
US20080249016A1
(en)
*
|
2000-09-18 |
2008-10-09 |
Sanos Bioscience A/S |
Use of GLP-2 in a combination treatment for bone-related disorders
|
|
US7371721B2
(en)
*
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
|
US6770620B2
(en)
|
2000-09-18 |
2004-08-03 |
Sanos Bioscience A/S |
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
|
|
US20070135345A1
(en)
*
|
2000-09-18 |
2007-06-14 |
Henriksen Dennis B |
Use of GLP-2 for the treatment or prevention, of bone-related disorders
|
|
DE60226702D1
(de)
*
|
2001-02-16 |
2008-07-03 |
Conjuchem Biotechnologies Inc |
Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
|
|
WO2004035624A2
(en)
*
|
2002-10-14 |
2004-04-29 |
Novo Nordisk A/S |
Glucagon - like peptide - 2 variants
|
|
DE602004031927D1
(de)
|
2003-02-04 |
2011-05-05 |
Novo Nordisk As |
Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
|
|
JP2007525425A
(ja)
*
|
2003-03-24 |
2007-09-06 |
ノボ ノルディスク アクティーゼルスカブ |
Ｇｌｐ−２誘導体
|
|
EP1633384B1
(en)
*
|
2003-05-15 |
2012-03-14 |
Trustees Of Tufts College |
Stable analogs of glp-1
|
|
JP2007536214A
(ja)
|
2003-12-16 |
2007-12-13 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Ｇｌｐ−１類似体
|
|
EP1708755B1
(en)
|
2004-01-21 |
2012-03-21 |
Novo Nordisk Health Care AG |
Transglutaminase mediated conjugation of peptides
|
|
DK1809318T3
(da)
|
2004-11-01 |
2013-09-08 |
Nps Pharma Inc |
Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
|
|
PL1877435T5
(pl)
*
|
2005-05-04 |
2021-09-27 |
Zealand Pharma A/S |
Analogi peptydu glukagonopodobnego 2 (GLP-2)
|
|
WO2007119101A2
(en)
*
|
2005-12-01 |
2007-10-25 |
Nps Allelix Corp. |
Assay system for glp-2 receptor ligands
|
|
CA2669806C
(en)
*
|
2006-11-08 |
2018-10-02 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (glp-2) analogues
|
|
EP2314616A1
(en)
*
|
2009-10-23 |
2011-04-27 |
Ferring B.V. |
Peptidic GLP-2 agonists
|
|
EP2627770B1
(en)
|
2010-10-15 |
2017-06-28 |
Cornell University |
Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders
|
|
CN102924589B
(zh)
*
|
2011-08-11 |
2016-08-24 |
中肽生化有限公司 |
胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
|
|
US20160137711A1
(en)
|
2011-09-12 |
2016-05-19 |
Amunix Operating Inc. |
Glucagon-like peptide-2 compositions and methods of making and using same
|
|
WO2013130683A2
(en)
|
2012-02-27 |
2013-09-06 |
Amunix Operating Inc. |
Xten conjugate compositions and methods of making same
|
|
AU2013255752B2
(en)
|
2012-05-03 |
2017-11-09 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (GLP-2) analogues
|
|
SG10201911851VA
(en)
|
2016-12-09 |
2020-02-27 |
Zealand Pharma As |
Acylated glp-1/glp-2 dual agonists
|
|
PE20200678A1
(es)
|
2017-06-16 |
2020-06-11 |
Zealand Pharma As |
Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2)
|
|
WO2020020904A1
(en)
|
2018-07-23 |
2020-01-30 |
Zealand Pharma A/S |
Therapeutic uses of glp-2 agonists
|